Kansas City Spring Learning Program
Join us for a complimentary educational event this spring, where you can network with colleagues, earn 2.5 CE contact hours and learn more about PCNA. Hosted by the Kansas City Chapter.
PCNA members and non-members are welcome to register and attend. Please share this with colleagues and friends.
Agenda
8:30 – Introduction and Welcome
8:45 – Impacts of SGLT2s and GLP1s on CVD, Diabetes, and Renal Function
9:45 – Lipids/Lipoprotein a/PCSK9i
10:15 – Brunch
10:45 – Pre-Eclampsia: Overview of Physiology and Future Vascular Risk
11:15 – Diagnosis, Disparities, and Opportunities to Impact Patients with Peripheral Artery Disease
11:45 – Closing
Presentation Topics
Impacts of SGLT2s and GLP1s on CVD, Diabetes, and Renal Function (1 CE)
Learning Objectives
- Explain the role, function, and side effects of SGLT2 inhibitors and GLP1 receptor agonists.
- Review the cardio-protective effects of SGLT2is and GLP1 RAs.
- Discuss the weight loss benefits of GLP1 RAs and SGLT2is.
- Summarize the renal benefits for patients with T2DM prescribed SGLT2is or GLP1 RAs.
- Apply patient and provider tools to enhance access and adherence to medication regimen.
Lipids/Lipoprotein a/PCSK9i (0.5 CE)
Learning Objectives
- Discuss the 2018 AHA/ACC Guidelines on the Management of Blood Cholesterol
- Understanding atherosclerosis and cholesterol’s role
- Lipid lowering pharmacology
Pre-Eclampsia: Overview of Physiology and Future Vascular Risk (0.5 CE)
Learning Objectives
- Learn about the prevalence and risk factors for preeclampsia
- Discuss the physiology of pregnancy as a 9-month stress test
- Discuss long term consequences of pre-eclampsia including higher risk of hypertension, atherosclerotic disease and stroke
Diagnosis, Disparities, and Opportunities to Impact Patients with Peripheral Artery Disease (0.5 CE)
Learning Objectives
- Understand how to diagnosis PAD by physiologic and/or anatomic vascular testing
- Recognize important disparities in PAD care
- Educate patients about how lifestyle modification and medications can reduce secondary CV risk and improve QOL